Stepan Co

Stepan Co (SCL) Market Cap

Stepan Co has a market capitalization of $1.46B.

Price: $64.14

-0.93 (-1.43%)

Market Cap: 1.46B

NYSE · time unavailable

CEO: Luis E. Rojo

Sector: Basic Materials

Industry: Chemicals - Specialty

IPO Date: 1973-02-21

Website: https://www.stepan.com

Stepan Co (SCL) - Company Information

Market Cap: 1.46B|Sector: Basic Materials

Company Profile

Stepan Company, together with its subsidiaries, produces and sells specialty and intermediate chemicals to other manufacturers for use in various end products in the United States, France, Poland, the United Kingdom, Brazil, Mexico, and internationally. It operates through three segments: Surfactants, Polymers, and Specialty Products. The Surfactants segment offers surfactants that are used in consumer and industrial cleaning and disinfection products, including detergents for washing clothes, dishes, carpets, and floors and walls, as well as shampoos and body washes; and other applications, such as fabric softeners, germicidal quaternary compounds, disinfectants, lubricating ingredients; emulsifiers for spreading agricultural products; and industrial applications comprising latex systems, plastics, and composites. The Polymers segment provides polyurethane polyols that are used in the manufacture of rigid foam for thermal insulation in the construction industry, as well as a base raw material for coatings, adhesives, sealants, and elastomers (CASE); polyester resins used in coating applications; specialty polyols, such as CASE and powdered polyester resins; and phthalic anhydride that is used in unsaturated polyester resins, alkyd resins, and plasticizers for applications in construction materials, as well as components of automotive, boating, and other consumer products. The Specialty Products segment offers flavors, emulsifiers, and solubilizers for use in food, flavoring, nutritional supplement, and pharmaceutical applications. Stepan Company was founded in 1932 and is headquartered in Northbrook, Illinois.

Analyst Sentiment

83%
Strong Buy

From 1 Active Polls

1Y Forecast: $75.00

▲ +16.9% Potential Upside

Consensus Target Metrics

Low Bound

$75

Median

$75

High Bound

$75

Average

$75

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$75.00
▲ +16.93% Upside
Low Target
$75.00
17% Risk
Median Target
$75.00
17% Mid
High Target
$75.00
17% Max
Consensus
Buy
3 / 3 Buys

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

📊 Historical Valuation Multiples

Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.

Fiscal QuarterTTMQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Period EndingTrailing 12MJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024
Market Cap ($M)1,4571,2761,1441,0841,0911,2481,2621,4781,764
Enterprise Value ($M)1,7011,5201,7161,6421,6801,8821,8852,0612,361
Price to Earnings Ratio (P/E)-534.5013.93-6.9053.8225.3727.2916.00107.8318.75
Price/Earnings-to-Growth Ratio (PEG)1.06-0.76112.901.24
Price to Sales Ratio (P/S)0.601.861.891.961.852.102.132.813.23
Price to Book Ratio (P/B)1.211.050.960.870.871.011.051.261.45
Price to Free Cash Flow Ratio (P/FCF)-75.66-81.98-34.8427.13-86.64-48.8846.0621.36
Enterprise Value to Sales (EV/Sales)2.222.842.962.853.163.183.924.32
Enterprise Value to EBITDA (EV/EBITDA)10.3920.76-104.1532.3129.9638.0132.6157.9145.04
Debt to Equity Ratio1.490.200.600.560.570.580.610.580.61

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 STEPAN (SCL) — Investment Overview

🧩 Business Model Overview

STEPAN is a specialty chemicals manufacturer focused on surfactants and surface-active formulations used across personal care, home care/detergents, and industrial applications, along with polyurethane-related products and other formulated chemical specialties. The value chain typically starts with commodity-derived and other industrial feedstocks, which are processed into intermediate chemistries (e.g., surface-active agents and polyurethane building blocks). These inputs are then converted into higher-performance products tailored to customer formulations, such as wetting, emulsifying, cleaning, dispersion, and foam-control solutions.

Revenue is driven by the ability to supply consistent performance at industrial scale, supported by technical application support and formulation know-how. Customer stickiness is enhanced because many products are qualified through formulation trials, regulatory/quality documentation, and performance benchmarking, creating practical barriers to switching suppliers.

💰 Revenue Streams & Monetisation Model

STEPAN monetizes through a portfolio of industrial and performance chemical products where margins are influenced by the spread between input costs and finished-product pricing, plus the mix of higher-value specialties versus more commoditized outputs. The model is not “purely recurring” in a software sense; however, the company can exhibit repeat purchase behavior due to qualified supply, long-term customer relationships, and ongoing demand from end-market production cycles.

  • Product-driven revenue: Surfactant and specialty chemical sales tied to customer production volumes in cleaning, personal care, coatings, and related industrial segments.
  • Margin drivers: (1) operational efficiency and asset utilization, (2) specialty mix (performance-based products generally carry better pricing power than basic intermediates), and (3) raw-material pass-through versus lagged pricing/contracting.
  • Application value: Pricing reflects performance attributes (e.g., stability, compatibility, end-use efficiency), not only chemical composition. This supports healthier margins when demand shifts toward formulation-level solutions.

🧠 Competitive Advantages & Market Positioning

The core moat is a combination of high customer switching costs and process/scale competence, with performance differentiation that matters at the formulation level.

  • Switching costs / qualification moat: Customers often qualify surfactant systems through technical trials, documentation, and performance testing in their specific processes (pH/temperature tolerance, stability, foam characteristics, skin/hair compatibility for personal care, and regulatory expectations for end products). This makes supplier changes operationally costly and time-consuming.
  • Operational and know-how advantages: Surfactants and polyurethane intermediates are sensitive to manufacturing quality, consistency, and impurity profiles. Maintaining yield, specifications, and reliability can be difficult to replicate quickly by smaller entrants.
  • Portfolio breadth: Cross-application coverage can help balance end-market seasonality and support customer “solution” offerings rather than single-commodity substitution.

Competitive benchmarking (primary peers):

  • Croda (CDR) — stronger emphasis on consumer-facing and specialty ingredients, with broader lifestyle/personal care exposure.
  • Evonik (EVK) — diversified specialty chemicals with extensive additive and performance materials portfolios, including surfactant-adjacent offerings.
  • Huntsman — more prominent in polyurethanes and related industrial materials, competing in polyurethane-linked chemical solutions.

Positioning contrast: While peers may be more diversified across end markets and product classes, STEPAN’s competitive stance is anchored in surface-active and polyurethane-related performance chemistry where qualification and formulation integration favor established suppliers with reliable manufacturing and technical application support.

🚀 Multi-Year Growth Drivers

  • Demand resilience in cleaning and hygiene: Elevated structural demand for hygiene and cleaning products supports underlying consumption of surfactant systems in developed and emerging markets.
  • Formulation complexity and performance upgrades: Regulatory and consumer requirements drive shifts toward products that perform under specific conditions (water hardness, temperature ranges, mildness targets, and stability). This favors suppliers with application engineering capabilities.
  • Polyurethane and industrial coatings ecosystem: Polyurethane-related products feed coatings, foams, and specialty industrial applications. Product adoption is tied to material performance improvements and end-use durability/efficiency.
  • Supply reliability and qualification-driven share retention: Specialty chemical markets can exhibit “stickiness” once plants and formulations are qualified. A differentiated supplier can defend share through performance and continuity rather than pricing alone.
  • Operational excellence and mix management: Over a 5–10 year horizon, improvements in asset reliability, specialty mix, and manufacturing efficiency can compound results even without major end-market surprises.

⚠ Risk Factors to Monitor

  • Commodity feedstock volatility: Input costs for industrial chemicals and derived feedstocks can swing, and margins depend on the speed and extent of pricing response.
  • End-market cyclicality: Surfactant demand is influenced by consumer/home-care cycles and industrial activity (coatings, lubricants, and related uses), creating earnings variability around macro conditions.
  • Environmental, regulatory, and compliance costs: Specialty chemicals face evolving environmental standards (emissions, wastewater, hazardous handling). Compliance and capital requirements can be significant.
  • Operational execution risk: Plant outages, yield issues, and supply disruptions can impair shipments and margin structure. Specialty chemical customers typically value reliability, so disruptions can have outsized impact.
  • Customer concentration and contract terms: Large customers can negotiate pricing and contract structures; adverse terms or reduced volumes can pressure profitability.

📊 Valuation & Market View

Specialty chemicals are often valued using EV/EBITDA and earnings power frameworks, with multiples reflecting both (1) normalized margins and (2) perceived durability of specialty mix and customer qualification. Because earnings can be sensitive to commodity spreads and utilization, valuation typically re-rates when the market gains confidence in:

  • Margin sustainability (specialty mix and cost discipline)
  • Consistency of demand (less exposure to pure commoditization)
  • Operational reliability (stable output, fewer disruptions)
  • Effective pricing-to-cost dynamics (ability to manage spread volatility)

Ultimately, investors look for evidence that high-performance products and qualified customer relationships can offset cyclical end-market pressure.

🔍 Investment Takeaway

STEPAN presents an evergreen specialty-chemicals thesis centered on formulation-driven switching costs, manufacturing reliability, and performance differentiation in surfactants and polyurethane-related specialties. The investment case is strengthened when specialty mix and operational execution stabilize margin structure against commodity volatility, enabling the company to compound earnings power through qualified customer relationships and end-market demand for high-performance cleaning and industrial chemical solutions.


⚠ AI-generated — informational only. Validate using filings before investing.

📰 Market News & Coverage

15 Stories Available

Real-time institutional reporting and market updates for SCL.

marketbeat.com2026-07-30

Stepan Q2 Earnings Call Highlights

Stepan NYSE: SCL reported higher second-quarter earnings as broad-based volume growth, margin recovery and early savings from its Project Catalyst program lifted results, while management cautioned that some demand may have been pulled forward amid geopolitical and raw-material uncertainty.

defenseworld.net2026-07-30

Stepan (NYSE:SCL) Shares Gap Up on Strong Earnings

Stepan Company (NYSE: SCL - Get Free Report) shares gapped up prior to trading on Wednesday after the company announced better than expected quarterly earnings. The stock had previously closed at $58.01, but opened at $62.71. Stepan shares last traded at $61.8130, with a volume of 23,201 shares traded. The basic materials company reported $1.18 earnings

seekingalpha.com2026-07-29

Stepan Company (SCL) Q2 2026 Earnings Call Transcript

Stepan Company (SCL) Q2 2026 Earnings Call Transcript

zacks.com2026-07-29

Stepan Co. (SCL) Surpasses Q2 Earnings and Revenue Estimates

Stepan Co. (SCL) came out with quarterly earnings of $1.18 per share, beating the Zacks Consensus Estimate of $0.61 per share. This compares to earnings of $0.52 per share a year ago.

prnewswire.com2026-07-29

Stepan Declares Quarterly Dividend

NORTHBROOK, Ill., July 29, 2026 /PRNewswire/ -- Stepan Company (NYSE: SCL) today reported: The Board of Directors of Stepan Company has declared a quarterly cash dividend on the Company's common stock of $0.395 per share.

prnewswire.com2026-07-29

Stepan Reports Second Quarter 2026 Results

NORTHBROOK, Ill., July 29, 2026 /PRNewswire/ -- Stepan Company (NYSE: SCL) today reported: Second Quarter 2026 Highlights Reported net income was $22.9 million, up 102% versus the prior year.

seekingalpha.com2026-07-18

My Top 5 Dividend Picks For July

July's top 5 dividend picks—PEP, CUBE, NLY, SCL, CMCSA—offer an average 16.3% expected annual total return and 6.0% yield, all trading at deep discounts. I rate PepsiCo (PEP) a Strong Buy, projecting a 17.2% annual return and a 30.5% discount to fair value, with transitory headwinds expected to subside. CubeSmart (CUBE), Annaly Capital (NLY), Stepan (SCL), and Comcast (CMCSA) are all Buys, each positioned for double-digit returns as macro conditions normalize.

seekingalpha.com2026-07-10

Stepan Company's Discount Isn't Over Yet

Stepan Company remains a 'buy' due to attractive valuation, despite recent underperformance versus the S&P 500. Recent results show mixed fundamentals: revenue growth driven by Surfactants, but profitability pressured by restructuring charges and raw material costs. Project Catalyst targets $100 million in pre-tax cost savings over two years, with 60% expected this year and the remainder next.

prnewswire.com2026-07-08

Stepan to Announce Second Quarter 2026 Results on July 29, 2026

NORTHBROOK, Ill., July 8, 2026 /PRNewswire/ -- Stepan Company (NYSE: SCL) will issue its second quarter 2026 earnings results on Wednesday, July 29, 2026 at approximately 7:00 a.m.

seekingalpha.com2026-06-05

Dividend Champion, Contender, And Challenger Highlights: Week Of June 7

A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.

gurufocus.com2026-05-01

Stepan Co (SCL) Stock Up 3.1% and Still Undervalued -- GF Score: 77/100

On May 01, 2026, Stepan Co (SCL) shares rose 3.1% to a current price of $51.59. This move comes amid a 52-week trading range that has seen a high of $68.00 and

seekingalpha.com2026-04-28

Stepan Company (SCL) Q1 2026 Earnings Call Transcript

Stepan Company (SCL) Q1 2026 Earnings Call Transcript

zacks.com2026-04-28

Stepan Co. (SCL) Beats Q1 Earnings Estimates

Stepan Co. (SCL) came out with quarterly earnings of $0.45 per share, beating the Zacks Consensus Estimate of $0.21 per share. This compares to earnings of $0.84 per share a year ago.

prnewswire.com2026-04-28

Stepan Declares Quarterly Dividend

NORTHBROOK, Ill., April 28, 2026 /PRNewswire/ -- Stepan Company (NYSE:SCL) today reported: The Board of Directors of Stepan Company has declared a quarterly cash dividend on the Company's common stock of $0.395 per share.

prnewswire.com2026-04-28

Stepan Reports First Quarter 2026 Results

NORTHBROOK, Ill., April 28, 2026 /PRNewswire/ -- Stepan Company (NYSE: SCL) today reported: First Quarter 2026 Highlights Reported net income was a $41.4 million loss versus $19.7 million of income in the prior year.

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-03-31

"SCL reported Q1’26 revenue of $604.5M and net income of -$41.4M (EPS -$1.81). Compared with Q4’25, revenue rose to $604.5M from $553.9M (+9.2% QoQ), but profitability deteriorated materially as net income swung from +$5.0M to -$41.4M. On a YoY basis, revenue in Q1’26 was slightly higher than Q1’25 ($604.5M vs. $593.3M, +1.9% YoY), while net income fell sharply (-$41.4M vs. +$19.7M, down ~-310%). Over the four-quarter trend, margins clearly contracted: gross margin declined to ~10.7% from ~12.7% in Q1’25, and net margin moved from +3.3% (Q1’25) to -6.8% (Q1’26). Cash flow also weakened versus prior periods. Operating cash flow was +$16.9M in Q1’26, down from +$59.99M in Q4’25, and free cash flow was +$16.9M (capex shown as zero in the cash flow line item). The company continues to pay dividends (about -$9.0M) but with negative earnings, dividend coverage is pressured. Balance sheet resilience is mixed: total assets were $2.33B and equity increased to ~$1.19B, while leverage remains meaningful with net debt of ~$525M. On total shareholder returns, the stock price is $51.42 with only +9.5% 1Y momentum, so returns appear more value/defensive than high-momentum."

Revenue Growth

Neutral

Revenue improved QoQ (+9.2% to $604.5M) but was only modestly up YoY (+1.9% vs. $593.3M).

Profitability

Neutral

Net income swung from +$5.0M (Q4’25) to -$41.4M (Q1’26) and fell from +$19.7M YoY (down ~310%). Net margin contracted to -6.8% from +3.3% (Q1’25).

Cash Flow Quality

Neutral

Operating cash flow fell to +$16.9M from +$60.0M QoQ and earnings are negative. Dividends were still paid (~-$9.0M), so cash/earnings coverage looks weaker.

Leverage & Balance Sheet

Fair

Assets were stable near $2.33B; equity rose to ~$1.19B. Net debt increased to ~$525M, indicating leverage remains a watch item but the balance sheet does not show collapse.

Shareholder Returns

Caution

1Y price change is +9.47% (no >20% momentum). Dividend yield is ~0.8%, so total return support is limited given current negative earnings.

Analyst Sentiment & Valuation

Caution

Street target consensus is $75 vs. current ~$51.42 (implied upside), but profitability deterioration reduces confidence in near-term fundamentals.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

Stepan’s Q2 2026 showed strong operating momentum: adjusted EBITDA rose 45% to $74.4M and adjusted EPS more than doubled to $1.18, supported by 6% organic volume growth (surfactants +7% organic, polymers +5% organic), margin recovery from pricing/pass-through execution, and early Project Catalyst benefits. However, cash flow weakened despite strong operations because working capital absorbed $58M amid higher raw material costs and increased sales; free cash flow was -$15M after $23M capex. The quarter also included restructuring impacts from the Fieldsboro NJ closure and decommissioning at Millsdale IL and Stalybridge UK, with full-year charges guided $75M–$80M. Management quantified customer pre-buying embedded in Q2 at $5M–$10M EBITDA tied to Iran uncertainty, with more variability possible in 2H. Outlook emphasizes ongoing ~$18M–$20M quarterly Catalyst savings run rate in 2026, additional $4M–$5M polymer turnarounds in 2H, and continued deleveraging to 2.5x net leverage.

AI IconGrowth Catalysts

  • Organic volume growth of 6% consolidated; surfactants +7% organic and polymers +5% organic, supporting broad-based demand recovery across end markets
  • Margin recovery driven by pricing actions and disciplined contractual raw-material pass-through, helping offset higher raw material costs
  • Project Catalyst initial benefits ramping in line with plan, contributing to quarterly performance and savings delivery

Business Development

  • New customer-product combinations in North America surfactants: 500 in the first half, driving double-digit growth in Tier 2/Tier 3 surfactants
  • Spray foam initiative traction in polymers: significant growth in spray foam product line referenced as a key driver of rigid polyols and PA growth

AI IconFinancial Highlights

  • Adjusted EBITDA $74.4M, up 45% YoY (+$23M), driven by higher surfactant volume earnings, margin recovery, and Project Catalyst savings
  • Net sales $684M, up 15% YoY, driven by higher selling prices, higher volume, favorable product/customer mix, and favorable currency translation
  • Adjusted EPS (diluted) $1.18, up 126% YoY; reported EPS $1.00 vs $0.50 prior year
  • Reported net income $22.9M; includes $5.1M pre-tax / $4.0M after-tax restructuring charge related to Fieldsboro NJ closure and decommissioning at Millsdale IL and Stalybridge UK
  • Restructuring cash impact ~$6M in the quarter; full-year restructuring charges guided $75M–$80M
  • Working capital build drove cash flow pressure: $58M working capital build (stronger sales and higher raw material costs); Free cash flow was negative $15M after capex of $23M
  • Net leverage improved to 2.5x from 2.7x in Q1 and 2.9x in Q2 2025

AI IconCapital Funding

  • Dividend paid $9M in the quarter (58th consecutive year of dividend growth)
  • Net debt ended at $534M; management emphasized continued deleveraging in 2H 2026
  • Capex executed at $23M in Q2; working capital investment ~$58M cited as the driver of negative free cash flow

AI IconStrategy & Ops

  • Project Catalyst: expected ~$100M pre-tax savings over two years with ~60% in 2026; committed $60M pre-tax savings delivered and described as driving ~$18M–$20M quarterly run-rate savings in 2026
  • Footprint optimization completed/transitioned: closure of Fieldsboro, New Jersey and decommissioning of select assets in Millsdale (IL) and Stalybridge (UK) during first half; volumes consolidated to more efficient sites
  • Organizational effectiveness: plan to reduce ~100 salaried positions, implemented in Q3 (majority of expenses expected in 2H 2026); minimizing impact via attrition and pausing external hiring
  • Manufacturing reliability: Millsdale production volumes and operating metrics improving; Pasadena TX ramp-up continuing and described as a critical enabler for specialty alkoxylates
  • Pasadena ramp status: almost 80% there; still needs to inch up toward 100% in subsequent quarters (utilization/efficiency improvement in 2027 referenced)

AI IconMarket Outlook

  • Management does not provide full guidance/forecast; stated for model purposes: pre-buying benefit estimated at $5M–$10M EBITDA from Q3 vs Q2 (midpoint referenced as in Q2)
  • Project Catalyst savings run rate: management expects ~$22M run-rate savings per quarter to progress toward full $100M (not yet full run-rate year) and continued interventions to reach next-year run rate
  • 2H 2026 polymer-side maintenance turnarounds expected to impact earnings/EBITDA by $4M–$5M

AI IconRisks & Headwinds

  • Geopolitical and raw material uncertainty: management noted ongoing Iran-conflict-related uncertainty and a potential persistence of just-in-case inventory behavior for “a few more months”
  • Raw material pricing dynamics remain volatile: coconut oil (CNO) down ~13% vs Q2 2025, offset by increases in other oil-related raw materials; management cautioned that Q3 could be slightly lower vs Q2 if normalization occurs
  • Soft demand in certain regions: polymers noted as lower volumes in Europe and Asia; Asia specifically “slightly lower on softer demand in China”
  • Market constraints in agriculture: fertilizer market challenges tied to Iran; ag growth slowed to low single digits in Q2
  • Cash generation risk from working capital: $58M working capital build in Q2 due to higher raw material costs and higher sales

Q&A: Analyst Interest

  • Topic: How much of Q2 volume/EBITDA strength was attributable to customer pre-buying? Management quantified pre-buying as $5M–$10M EBITDA (midpoint) embedded in Q2, linked to Iran-related uncertainty, and clarified it was expected to reverse heading into Q3 but not fully avoid ongoing inventory risk.
  • Topic: Spray foam growth trajectory in polymers and realistic expansion potential over 1–2 years. Management emphasized this is a “white space,” with historical lamination market growth high-single digits, and stated it would not provide an exact forecast. They highlighted the 3x volume growth from a low base and the intent to maintain market participation.
  • Topic: Margin drivers—pricing vs raw material inflation and whether the “worst” inflation impact was yet to flow through P&L. Management said they are not changing pass-through approach, but noted mixed raw material movements: CNO down ~13% vs Q2’25 while other oil-related inputs rose. They suggested Q3 could be slightly lower if normalization occurs and reiterated contractual pass-through discipline.

Sentiment: MIXED

Note: This summary was synthesized by AI from the SCL Q2 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

📋 Official Regulatory 10-K / 10-Q SEC Filings

Direct authenticated documentation links to audited SEC database reports for SCL.

SEC EDGAR Live Feed
Loading financial data and tables...
📁

SEC Filings (SCL)

© 2026 Stock Market Info — Stepan Co (SCL) Financial Profile